Effect of Pea Flour in Bread on Blood Glucose

Launched by ST. BONIFACE HOSPITAL · Apr 13, 2018

Keywords

ClinConnect Summary

A randomized, controlled, cross-over study designed to examine the post-prandial glycaemic response, metabolism of bioactives and appetite related sensations to 20% incorporation of yellow pea flour (untreated, heat treated with 0% moisture and heat treated with 10% moisture) into bread will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. Eligible participants who have provided consent will be asked to attend 4 clinic visits in a fasted state. Participants will be given bread containing 20% yellow pea flour at 3 visits and bread with 100% wheat flour at 1 v...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Generally healthy male or female, between the age of 18-40 years;
• • 2. Body mass index (BMI) 18.5-30.0 kg/m2;
• • 3. Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening, respectively;
• • 4. Willing to provide informed consent;
• • 5. Willing/able to comply with the requirements of the study.
• Exclusion Criteria:
• • 1. Pregnant or lactating;
• • 2. Medical history of diabetes mellitus, fasting blood glucose ≥6.1 mmol/L, HbA1c ≥6.0%, or use of insulin or oral medication to control blood sugar;
• • 3. Medical history of cardiovascular disease;
• • 4. Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg;
• • 5. Fasting plasma total cholesterol \>7.8 mmol/L;
• • 6. Fasting plasma HDL \<0.9 mmol/L;
• • 7. Fasting plasma LDL \>5.0 mmol/L;
• • 8. Fasting plasma triglycerides \>2.3 mmol/L;
• • 9. Major surgery within the last 3 months;
• • 10. Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;
• • 11. Medical history of liver disease or liver dysfunction (defined as plasma aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 times the upper limit of normal (ULN));
• • 12. Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥3 times the ULN));
• • 13. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
• • 14. Active treatment for any type of cancer within 1 year prior to study start;
• • 15. Shift worker (a system of employment where an individual's normal hours of work are in part, outside the period of normal working day; 6am and 8pm);
• • 16. Smoking, use of tobacco or a nicotine replacement product, and cannabis in any form (within the last 3 months);
• • 17. Allergies to peas or wheat;
• • 18. Aversion or unwillingness to eat study foods;
• • 19. Consuming \>4 servings of pulses per week;
• • 20. Use of any prescription or non-prescription drug, herbal or nutritional supplement known to affect glycaemia or appetite;
• • 21. Participation in another clinical trial, current or in the past 4 weeks;
• • 22. Unstable body weight (defined as \>5% change in 3 months) or actively participating in a weight loss program.
• • 23. Other medical, psychiatric, or behavioral factors that in the judgment of the principal Investigator may interfere with study participation or the ability to follow the intervention protocol;